| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 3,260 | 3,620 | 3,610 | 3,880 | 3,870 |
| Sales Growth | -9.94% | +0.28% | -6.96% | +0.26% | -2.03% |
| Net Income | -380 | -260 | -110 | -730 | -460 |
| Net Income Growth | -46.15% | -136.36% | +84.93% | -58.70% | +20.69% |
Cv Sciences Inc
(CVSI)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
CV Sciences Inc. is a life science company. Its operating segment consists of specialty pharmaceuticals and consumer products. Specialty pharma business segment is focused on developing and commercializing therapeutics utilizing synthetic Cannabidiol across several therapeutic areas. Consumer product business segment is focused on manufacturing, marketing and selling plant-based CBD products. It operates primarily in San Diego, California and Las Vegas, Nevada. CV Sciences Inc. is based in Las Vegas, United States.
Fiscal Year End Date: 12/31